About this trial
The objective of this trial is to assess efficacy and compliance of transcutaneous electrical stimulation of the upper airway dilator muscles in patients with obstructive sleep apnoea (TESLA) who do not tolerate continuous positive airway pressure (CPAP) therapy over a period of 3-months in the community and compare results against usual care (ongoing CPAP therapy), evaluate acceptability, comfort and adverse events, and record outcomes for provision of the health economics analysis. The proposed study will provide us with data about the efficacy of the domiciliary use of the intervention from a UK-based prospective, multi-centre and randomised controlled trial (Phase III). We will understand whether the primary outcome parameter, the apnoea hypopnea index (AHI), or the secondary outcomes (e.g. 4% oxygen desaturation index (ODI), the Epworth Sleepiness Scale (ESS), compliance and comfort, Functional Outcome of Sleep Questionnaires (FOSQ), European Quality of Life Questionnaire (EQ-5D)) are suitable measures to assess control of OSA using TESLA within reasonable acceptance for the patients to provide the analysis of healthcare resource usage for assessment of cost-efficacy and quality-adjusted life years (QALYs). Responder analysis will provide insights into gender, socio-economic background and endotypes to predict who most suitably benefits from this treatment.
Eligibility criteria
Qualifiers
Adult participants (≥18 years) who have OSA with an AHI between 5-40 events/hour, as measured by the baseline sleep study (3 nights off CPAP).
If the participant fails to use CPAP sufficiently, defined as use of CPAP for less than 4 hours/night on fewer than 70% of nights over a minimum period of 3 months prior to enrolment.
Adults with a body mass index (BMI) of 18.5-32.0 kg/m2 (inclusive)
Adults without significant anatomical obstruction in the upper airway (e.g., normal sized tonsils).
Disqualifiers
Hypercapnic patients (pCO2>6.0 kPa) or those with other features of obesity hypoventilation syndrome (elevated bicarbonate, HCO3- >28mmol/L).
Adults with significantly enlarged tonsils (size 3-4)
Adults with polyps or adenoids, hypoglossal nerve palsy,
Adults with notable medical co-morbidities that could potentially impact participation in or the achievement of the study's objectives (e.g., significant heart failure (New York Heart Association, NYHA class III-IV), recent myocardial infarction (within 3 months) and significant cardiac arrhythmias, uncontrolled hypertension).
Trial design
Treatments tested in this trial
- ZeusOSA
- CPAP
Treatment groups
Locations
Sponsors and collaborators
Zeus Sleep Ltd
Lead sponsor
Guy's and St Thomas' NHS Foundation Trust
Collaborator
King's College London
Collaborator
Royal Brompton & Harefield NHS Foundation Trust
Collaborator
Queen Victoria Hospital NHS Foundation Trust
Collaborator
The Queen Elizabeth Hospital
Collaborator
Imperial College Healthcare NHS Trust
Collaborator
AintreeNHSTrust
Collaborator
University of Southampton
Collaborator
Royal Papworth Hospital
Collaborator